GlassScriptPhysician profile
Basheer Tashtoush
NPI 1932548542
$2,975.70
in general payments reported to CMS, 2019-2025
24 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $368 · 2022: $305 · 2023: $18.82 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $296.33 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $293.68 | 2019-2020 | |
| Genentech USA, INC. | $280.05 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $274.67 | 2019-2023 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $273.63 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.35 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $242.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $233.24 | 2019-2022 | |
| Inari Medical, INC. | $196.63 | 2022 | |
| Jazz Pharmaceuticals INC. | $126.11 | 2019 | |
| Grifols USA, LLC | $68.29 | 2019 | |
| Mylan Specialty L.P. | $58.50 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $54.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.82 | 2019 | |
| Advanced Respiratory, INC | $40.27 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $35.94 | 2019 | |
| Allergan, INC. | $33.72 | 2019 | |
| United Therapeutics Corporation | $31.06 | 2019 | |
| Mallinckrodt Hospital Products INC. | $30.03 | 2020 | |
| Pfizer INC. | $28.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.11 | 2019 | |
| Insmed, INC. | $18.35 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.69 | 2020 | |
| Merck Sharp & Dohme LLC | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basheer Tashtoush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.